CB-5083

CB-5083 has been studied in 2 papers since 2025: none in people yet, 2 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 5, 2026: “Protein inhibitor reduced lung inflammation in mice”.

Intervention

2 papers study it8 findingsUpdated Nov 4, 2026

PubChem ChEBI

1 new paper in 30 daysSee all 2 papers on CB-5083

At a glance

The findings reach mice, none yet in people. 2 independent labs in 1 country; 1 trial, none about aging, 1 with no results posted.

None of its findings points the other way.

2 independent labs in 1 country
1 trial, none about aging, 1 with no results posted

Animals2

What did studies of CB-5083 find?

Studies of CB-5083 measured 8 outcomes; the most studied are lung inflammation (1 study), alveolar damage (1) and SIRT1 SUMOylation (1).

lung inflammation

downin mice1

1 study

CB-5083 decreases lung inflammation in mice (cigarette smoke exposure plus intranasal lipopolysaccharide challenge).
“In vivo, CB-5083 administration markedly ameliorated CS + LPS-induced alveolar damage, neutrophilic infiltration, and pro-inflammatory cytokine production”
Animalscigarette smoke exposure plus intranasal lipopolysaccharide challengelung
Protein inhibitor reduced lung inflammation in mice
Biochemical pharmacologyNov 4, 2026

Alveolar damage

downin mice1

1 study

CB-5083 decreases alveolar damage in mice (cigarette smoke exposure plus intranasal lipopolysaccharide challenge).
“In vivo, CB-5083 administration markedly ameliorated CS + LPS-induced alveolar damage, neutrophilic infiltration, and pro-inflammatory cytokine production”
Animalscigarette smoke exposure plus intranasal lipopolysaccharide challengelung
Protein inhibitor reduced lung inflammation in mice
Biochemical pharmacologyNov 4, 2026

SIRT1 SUMOylation

upin mouse cells1

1 study

CB-5083 increases SIRT1 SUMOylation in mouse cells (5% cigarette smoke extract exposure).
“Pharmacological inhibition of p97 with CB-5083 attenuated the senescent phenotype, restored SIRT1 stability and deacetylase activity, and enhanced SIRT1-SUMO1 conjugation.”
Cells5% cigarette smoke extract exposureTC-1 cells
Protein inhibitor reduced lung inflammation in mice
Biochemical pharmacologyNov 4, 2026

SIRT1 stability and deacetylase activity

upin mouse cells1

1 study

CB-5083 increases SIRT1 stability and deacetylase activity in mouse cells (5% cigarette smoke extract exposure).
“Pharmacological inhibition of p97 with CB-5083 attenuated the senescent phenotype, restored SIRT1 stability and deacetylase activity, and enhanced SIRT1-SUMO1 conjugation.”
Cells5% cigarette smoke extract exposureTC-1 cells
Protein inhibitor reduced lung inflammation in mice
Biochemical pharmacologyNov 4, 2026

Cellular senescence

downin mouse cells1

1 study

CB-5083 decreases cellular senescence in mouse cells (5% cigarette smoke extract exposure).
“Pharmacological inhibition of p97 with CB-5083 attenuated the senescent phenotype”
Cells5% cigarette smoke extract exposureTC-1 cells
Protein inhibitor reduced lung inflammation in mice
Biochemical pharmacologyNov 4, 2026

Trial sponsors

Cleave Biosciences
Company1 trialPhase 1120 people

Latest

1 paper in 12 months

Biochemical PharmacologyNov 5

Protein inhibitor reduced lung inflammation in mice

An experiment in mice exposed to cigarette smoke and a bacterial molecule found less lung damage and inflammation after a protein-blocking drug.An experiment in mice exposed to cigarette smoke and a bacterial molecule found less lung damage and inflammation after a protein-blocking drug.

Mouse studyInflammation